Clinical Trials Browser

Active not recruiting × enfortumab vedotin × 90 days × Clear all

NCT04960709 2026-06-04

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Phase 2 Active not recruiting

Carcinoma, Transitional Cell